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New treatments for psychotic disorders
In The Lancet Psychiatry, Daniel Freeman and colleagues1 
report the results from their trial that investigated 
the clinical eﬀ ects of an intervention targeting worry 
in patients with non-aﬀ ective psychosis. The authors 
accurately write in their Introduction that treatments 
for psychotic conditions, such as schizophrenia, need 
substantial improvement. The ﬁ rst-line treatment 
of schizophrenia—ie, antipsychotics—can suppress 
delusions and hallucinations, but patients still suﬀ er 
from other symptoms such as negative symptoms, and 
often report adverse side-eﬀ ects from the medication 
(eg, apathy, neurological side-eﬀ ects, serious weight 
gain, and sexual dysfunction). The percentage of 
non-compliance with medication in patients with 
schizophrenia is as high as 40–50%,2 and 74% of patients 
discontinue their medication within 18 months.3 
Furthermore, Wunderink and colleagues4 report that 
dose reduction or discontinuation of antipsychotics 
during the early stages of remitted ﬁ rst-episode 
psychosis is associated with superior long-term (7 years) 
recovery rates (40·4%) compared with the rates achieved 
with antipsychotic maintenance treatment (17·6%). 
Additionally, Morrison and colleagues5 reported that 
cognitive therapy signiﬁ cantly reduced psychiatric 
symptoms and seems to be a safe and acceptable 
alternative for people with schizophrenia and related 
disorders who have chosen not to take antipsychotic 
medication. In consideration of low patient compliance 
with antipsychotics,2,3 evidence for improved long-
term functional recovery with dose reduction or 
discontinuation of antipsychotic medication,4 and 
the promising results from trials of psychological 
treatments,5 intervention options for patients with a 
psychotic disorder are clearly needed that are eﬀ ective, 
have fewer side-eﬀ ects, and are more acceptable to 
some patients than antipsychotics. 
Freeman and colleagues1 show in their randomised 
controlled trial of 150 patients with persecutory 
delusions that a six session, worry-reduction cognitive 
behaviour therapy (CBT) intervention added to standard 
care led to signiﬁ cant reductions in both worry (mean 
diﬀ erence 6·35 [SE 1·56] Penn State Worry Questionnaire 
units, 95% CI 3·30–9·40; p<0·001) and persecutory 
delusions (mean diﬀ erence 2·08 [SE 0·73] Psychotic 
Symptoms Rating Scale units, 95% CI 0·64–3·51; 
p=0·005) compared with standard care alone. The 
intervention aimed to reduce time worrying and did 
not directly target the delusions themselves. In addition 
to signiﬁ cant reduc tions in worry and persecutory 
delusions, the inter vention also led to signiﬁ cant 
improvements in overall psychiatric symptoms, paranoid 
thinking, psychological wellbeing, and rumination. 
Furthermore, the results of a mediation analysis were 
consistent with a causal role for worry in paranoia (ie, 
the change in worry accounted for 66% of the change in 
delusion). 
A few important questions about this study 
need to be addressed in future research. First, can 
the worry CBT intervention in combination with 
modular interventions targeting other key causal 
factors, such as sleep disturbance and low self-
esteem, reduce the dose of antipsychotics needed 
for patients with psychotic disorders? Second, do 
these modular interventions improve outcome for 
patients with an At Risk Mental State (ARMS) for 
developing a ﬁ rst psychosis6 when they are added 
to a more comprehensive CBT? A CBT developed 
especially for ARMS patients that targets the eﬀ ects of 
cognitive biases, such as jumping to conclusions, and 
encompassing psychoeducation about prepsychotic 
symptoms, has been shown to reduce the chance 
of transition to a ﬁ rst psychosis by about 50%.7,8 The 
ﬁ rst treatment option for ARMS patients should be 
CBT because there is cumulative evidence that this 
type of intervention is eﬀ ective and without adverse 
eﬀ ects in this patient group,9 and international 
treatment guidelines advise against treating ARMS 
patients with antipsychotics.10 In ARMS patients, 
worrying, sleep disturbances, negative eﬀ ects of 
reasoning biases, and low self-esteem often have 
an important role in the onset, maintenance, and 
exacerbation of psychotic symptoms. Targeting these 
factors with optional modules that are incorporated 
in a more comprehensive CBT could further improve 
prognosis in ARMS patients. Intervention in the 
prepsychotic phase is more eﬀ ective than intervention 
during a ﬁ rst psychotic episode because patients 
are in a more treatment-responsive stage of illness, 
in which psychosocial and neurobiological damage 
is less extensive. Clinical experience and research 
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In The Lancet Psychiatry, Louisa Degenhardt and 
colleagues1 aim to establish how deﬁ nitions of opioid 
use disorder or dependence in WHO’s ICD-10 and 
ICD–112 and the American Psychiatric Association’s 
DSM-IV and DSM-53 classiﬁ ed individuals in POINT, 
an Australian community sample of people prescribed 
pharmaceutical opioids for chronic non-cancer pain. 
This study is both relevant and important for public 
health care due to increasing rates of long-term 
prescribing of opioids for chronic pain in many high-
income countries, particularly the USA, Australia, and 
Canada,4,5 and growing concern about the associated 
increases in problematic use of and dependence to 
these opioids.6,7 Accurate diagnosis of dependence and 
disorder in this group is needed to target treatment 
effectively. Moreover, DSM-5 was released in 20133 
and the ICD system is currently undergoing revision, 
and so it is timely to examine these classification 
systems.2
The study by Degenhardt and colleagues1 provides 
empirical evidence for how different diagnostic 
criteria for opioid dependence or disorder classified 
individuals receiving opioids for pain. Sampling 
1422 people who had been taking strong opioids 
for their pain for a median of 4 years (IQR 1·5–10·0), 
the authors reported that 8·5–9·9% of participants 
met lifetime criteria for dependence when they used 
DSM-IV, ICD-10, and ICD-11. 20·8% of participants 
fit criteria for use disorder in DSM-5 (when 
restrictions were applied). DSM-5 differs from other 
classifications by using a single category in which 
dependence and problematic use are measured on a 
continuum (mild, moderate, and severe use disorder) 
and in which physiological responses of tolerance 
and withdrawal are excluded if the patient is being 
prescribed opioids for chronic pain and adheres to 
their prescription. When tolerance and withdrawal 
were included, irrespective of the patient’s adherence, 
results show that a patient can be more easily 
engaged in treatment if distress is prominent while 
illness-insight is still largely intact, leading to better 
treatment outcomes. 
In conclusion, the study by Freeman and colleagues1 
is an important contribution that ﬁ ts with the 
current movement towards evidence-based, benign 
treatment options for patients with a psychosis 
spectrum disorder. Furthermore, the study ﬁ ts with 
the trend towards transdiagnostic interventions in 
psychiatry. Cumulative evidence suggests that the 
DSM categories for mental disorders might not be 
valid, both from a biological and a clinical perspective.11 
Worrying occurs in many psychiatric disorders, both 
in the ARMS phase and in later stages, and targeting 
worry could lead to improved outcomes, irrespective 
of DSM diagnosis. Freeman and colleagues’ study1 
has important implications for clinical practice and 
research, and I hope their treatment manual will be 
widely disseminated soon. 
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